Skip to content
Menu

HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice TargetStock Split

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Lander Egaña Gorroño maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and raises the price target from $8 to $52.

HC Wainwright & Co. analyst Lander Egaña Gorroño maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and raises the price target from $8 to $52.

Read at benzinga.com